亲爱的疫苗研究者、专家和行业领袖，我们怀着极大的兴奋之情，诚挚地邀请您参加即将在2024年3月于上海举办的Vaccine Innovation Forum（VIF） World 2024（第5届疫苗创新国际论坛）。这将是全球疫苗领域最引人瞩目的盛会之一，汇聚了来自世界各地的疫苗开发和免疫领域的顶尖专家、研究人员、政策制定者和产业领袖。
 

会议主题："疫苗的未来：推动全球健康"

学术顾问委员会：
Bin Wang, CSO, Advaccine/Professor, Fudan University, China
David Weiner, Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania, USA
Chunlin Xin, Vice President, Cansino Biologics, China
Yuanqing Liu, CSO, Immorna China, China
Heinrich Haas, Former VP, Formulation& Drug delivery, BioNtech, Germany
Alain Bouckenooghe, CSO, Hilleman Laboratories, Singapore
Shaowei Li, Professor, Xiamen University, China
Sergey Arakelov, Sci. Dir., St. Petersburg Scientific Research Institute of Vaccines and Sera of the FMBA of Russia
Kiat Ruxrungtham, Director of Chula VRC, Chulalongkorn University,Thailand
Dexiang Chen, Chairman& General Manager, Maxvax Biology, China
Anna Du, Senior Program Officer, China Country Office, Bill & Melinda Gates Foundation, China
Li Shi, Board Chairman, Immune-Path Bio,China
Sean Du, Head, External R&D Asia Pacific, Global R&D, Sanofi Pasteur, China
Yuan Yuan, China Country Representative, Business & Alliance Management Lead, PATH, China
Petro Terblanche, CEO, Afrigen Biologics, South Africa

为什么参加：
前沿见解：发掘最新的疫苗研究发现、突破性技术和发展策略。
全球影响：为全球公共卫生作出贡献，提高全球免疫水平。
大流行准备：从过去的疫情中汲取经验教训，探讨通过创新疫苗开发来增强全球准备。
平等获取：强调所有人群对疫苗的平等获取的重要性，解决不平等问题。
中国的贡献：探讨中国在疫苗研究和生产方面的重要进展。

关键议题：
创新疫苗开发进展
新疫苗平台和技术
基于RNA技术的疫苗及疗法
动物疫苗
癌症疫苗与免疫疗法
生物工艺和制造
临床试验与疫苗安全性
市场准入、监管和国际合作
佐剂、制剂和递送技术

早期确认演讲嘉宾：
George Siber, President, Siber Biotechnologies LLC, USA
Rajinder Suri, CEO, DCVMN International, India
Petro Terblanche, CEO, Afrigen Biologics, South Africa
Simon Graham, Professor, The Pirbright Institute, UK
Kar Muthumani, CSO, GeneOne Life Science, USA
Shan Lu, Professor, University of Massachusetts Medical School, USA
Joon Haeng Rhee, Professor, Chonnam National University Medical School, South Korea
Nikolai Petrovsky, Founder, Vaxine, Australia
Hun Kim, President of Global R&BD, SK Bioscience, South Korea
Dal-Hee Min, CTO, Lemonex, South Korea
Kate Antrobus, Chief Investment Officer, Univercells, Belgium
Kiat Ruxrungtham, Director of Chula Vaccine Research Center, Chulalongkorn University, Thailand
Bin Wang, CSO, Advaccine/Professor, Fudan University, China
David Weiner, Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania, USA
Andrew Wong, BD Director, Walvax/ General Manager, Shanghai Wotai Biotechnology, China
Nicaise Ndembi, Chief Science Advisor, Africa Centres for Disease Control and Prevention, Ethiopia
Jeffrey Ulmer, President, TechImmune, USA
Jicui Dong, Head, Local Production and Assistance Unit Regulation & PQ, Access to Medicines and Health Products Division,WHO, Switzerland
Ramesh Matur, Sr VP, Head R&D, Biological E, India
Kutub Mahmood, Scientific Director at PATH, USA
Ed Lavelle, Professor, Trinity College Dublin, Ireland
Mahesh Kumar, Senior Vice President, Global Biologics R&D, Zoetis, USA
Abdul Muktadir, Chairman and Managing Director, Incepta Pharmaceuticals/ Incepta Vaccine, Bangladesh
Francesco Berlanda Scorza,VP R&D, Global Health R&D Vaccines Head and GVGH Institute, GSK, Belgium
Baoming Jiang, Senior Scientist, Division of Viral Diseases- CDC, USA
James Wai Kuo Shih, Senior Advisor, Xiamen Innovax Biotech, ChinaHaibo Li, Professor, Army Medical University, China
Ken Ishii, Director, International Vaccine Design Center, Professor, University of Tokyo, Japan
Yu-shen Hsu, Chairman/Acting President, Advagene, Taiwan, China
Frank Chang, CSO, Reber Genetics, Taiwan, China
Shibo Jiang, Professor, Fudan University, China
Zoltan Kis, Lecturer, University of Sheffield, UK
Jeff Zhu, CEO, Reinovax Biologics, China
Michel De Wilde, Owner, MDW Consultant,LLC, Former SVP of R&D, Sanofi Pasteur, USA
Zhizheng Hu, Associate Director, RA, MSD
持续更新中
 
演讲、赞助、参展、墙报及会议详情，请扫码：